A Phase I clinical trial evaluating the safety/tolerability and pharmacokinetic characteristics of HW211026 ointment after a single dose in healthy volunteers
Latest Information Update: 30 Jan 2026
At a glance
- Drugs HW 211026 (Primary)
- Indications Actinic keratosis
- Focus Adverse reactions
- Sponsors Wuhan Humanwell Innovative Drug Research and Development Center
Most Recent Events
- 30 Jan 2026 New trial record